Myriad outcomes
Restores
tissue
Vascularized tissue coverage in as little as 7 days and volumetric fill in 3 weeks.1-4
Minimal complications
Low infection and graft loss rates, even in contaminated defects.1-8
Single
application
A median of one product application1-8
Clinical evidence supporting our treatment outcomes using Myriad
| Reference | Number of defects | Time to tissue coverage/fill (Weeks) | Infection rate | Median # of product applications |
|---|---|---|---|---|
| Lawlor et al. (1) Lower extremity reconstruction | 130 | 5.5±0.4 w | 0% | 1.0 |
| Cormican et al.(2)Traumatic and acute defects | 13 | 3.3±1.3 w | 0% | 1.0 |
| Taarea et al.(4) Emergency open abdomen | 3 | 3.5±1.3 w | 0% | 1.0 |
| Bosque et al.(3)Lower extremity reconstruction | 50 | 3.7±3.2 w | 0% | 1.0 |
| Chaffin et al.(5)Pilonidal sinus | 6 | - | 0% | 1.0 |
| Chaffin et al.(6)Hidradenitis suppurativa | 8 | - | 0% | 1.0 |
| Desvigne et al.(11)Non-healing wounds | 9 | - | 11% | 1.0 |
| Hsu et al. (26) Anal fistula | 14 | - | 0% | 1.0 |
| Bohn et al.(7) Exposed structures | 6 | 1-6 w | 0% | 1.0 |
Myriad advantages
Volumetric
Fill
Quickly fills complex defects and dead space with organized native tissue.1-6
Rapid vascularization
Enables early tissue development to allow native immune protection and coverage of avascular structures.1-4, 7, 15-17
Sustained
activity
Modulates inflammation to initiate and maintain constructive remodeling.1-10, 12, 14
The Residual Myriad difference
- As Myriad incorporates into the developing tissue, it is broken down and remodeled
- As it integrates, Residual Myriad is observed as varying levels of intact product (typically a creamy golden substance)
- Until completely remodeled , Residual Myriad continues to add structure and biology to the developing tissue
- Residual Myriad should be expected, and is beneficial for the formation of functional tissue
Myriad surgical case studies
Initial Presentation
Week 8
Michael Cormican, MD
Initial Defect
Week 14
Anthony J. LaLama, DPM
Initial Defect
Day 59
Romeo P. Massoud, MD
Initial Defect
Flap Advancement and Closure
Abigail E. Chaffin MD, FACS, CWSP, MAPWCA
Pre-operative Assessment
Week 25
William Vassy, MD, FCCS
Initial Assessment
Day 56
Michael Cormican, MD
Pre-operative Assessment
Week 21
Michael Cormican, MD
Initial Presentation
Week 25
Michael Cormican, MD
Pre-operative Assessment
Day 36
Michael Cormican, MD
A portfolio for soft tissue repair
Myriad Matrix™
Multiple layers of AROA ECM™ to enable regeneration of organized, functional tissue.
Myriad Morcells™
A conformable graft of morselized Myriad. Ideal for irregular, tunneled or undermined wounds.
Myriad Morcells Fine™
A finer particulate of Myriad Morcells. Ideal for irregular, tunneled or undermined wounds.
Ordering
Reimbursement
AROA ECM™
Our platform technology
Derived from ovine forestomach, the AROA ECM technology is a patented platform for our soft tissue repair and reconstruction portfolio. It regenerates functional tissue, enabling clinicians to achieve more for patients.
